The mechanisms of action of rituximab in the elimination of tumor cells

Seminars in Oncology

Volumn 30, Issue 1 SUPPL. 2, 2003, Pages 3-8

  Johnson, Peter ^a,b   Glennie, Martin ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FC RECEPTOR; INTERLEUKIN 10; PHOSPHOLIPASE; PREDNISONE; PROTEIN TYROSINE KINASE; RITUXIMAB; VINCRISTINE;

ANTIGEN BINDING; APOPTOSIS; CANCER CHEMOTHERAPY; CELL KILLING; CONFERENCE PAPER; CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; LIPID MEMBRANE; LYMPHOCYTE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

EID: 0037297117     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2003.50025     Document Type: Conference Paper

References (35)

1. McLaughlin P, Grillo-López AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
2. Colombat P, Salles G, Brousse N, et al: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 97:101-106, 2001
3. Hainsworth JD, Litchy S, Burris HA III, et al: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20:4261-4267, 2002
4. Ghielmini M, Schmitz SF, Cogliatti SB, et al: Maintenance treatment with 2-monthly rituximab after standard weekly x 4 rituximab induction significantly improves event-free survival in patients with follicular lymphoma. Ann Oncol 13;38, 2002 (suppl 2) (abstr)
5. Czuczman MS, Grillo-Lopez AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999
6. Czuczman MS, Fallon A, Mohr A, et al: Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 29:36-40, 2002 (suppl 2)
7. Davis TA, Maloney DG, Grillo-Lopez AJ, et al: Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and inter-, feron-alpha-2a. Clin Cancer Res 6:2644-2652, 2000
8. Kimby E: Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte-macrophage colony stimulating factor. Semin Oncol 29: 7-10, 2002 (suppl 6)
9. Einfeld DA, Brown JP, Valentine MA, et al: Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 7:711-717, 1988
10. Tedder TF, Engel P: CD20: A regulator of cell-cycle progression of B lymphocytes. Immunol Today 15:450-454, 1994
11. Kansas GS, Tedder TF: Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. J Immunol 147:4094-4102, 1991
12. Deans JP, Schieven GL, Shu GL, et al: Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2. J Immunol 151:4494-4504, 1993
13. Polyak MJ, Tailor SH, Deans JP: Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment J Immunol 161:3242-3248, 1998
14. Shan D, Ledbetter JA, Press OW: Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies Blood 91:1644-1652, 1998
15. Mathas S, Rickers A, Bommert K, et al: Anti-CD20- and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signaling pathways. Cancer Res 60:7170-7176, 2000
16. Polyak MJ, Deans JP: Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 99:3256-3262, 2002
17. Anderson DR, Grillo-Lopez A, Varns C, et al: Targeted anti-cancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 25:705-708, 1997
18. Winkler U, Jensen M, Manzke O, et al: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94:2217-2224, 1999
19. Golay J, Zaffaroni L, Vaccari T, et al: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95:3900-3908, 2000
20. Weng WK, Levy R: Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 98:1352-1357, 2001
21. Clynes RA, Towers TL, Presta LG, et al: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443-446, 2000
22. Koene HR, Kleijer M, Algra J, et al: Fc gamma RIIIa, 158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90:1109-1114, 1997
23. Cartron G, Dacheux L, Salles G, et al: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758, 2002
24. Deans JP, Kalt L, Ledbetter JA, et al: Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem 270:22632-22638, 1995
25. Shan D, Ledbetter JA, Press OW: Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48:673-683, 2000
26. Bubien JK, Zhou LJ, Bell PD, et al: Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 121:1121-1132, 1993
27. Kanzaki M, Shibata H, Mogami H, et al: Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells. J Biol Chem 270:13099-13104, 1995
28. Hofmeister JK, Cooney D, Coggeshall KM: Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 26:133-143, 2000
29. Ghetie MA, Bright H, Vitetta ES: Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 97:1392-1398, 2001
30. Byrd JC, Kitada S, Flinn IW, et al: The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: Evidence of caspase activation and apoptosis induction. Blood 99:1038-1043, 2002
31. Demidem A, Lam T, Alas S, et al: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12:177-186, 1997
32. Alas S, Bonavida B, Emmanouilides C: Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anticancer Res 20:2961-2966, 2000
33. Alas S, Emmanouilides C, Bonavida B: Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7:709-723, 2001
34. Alas S, Bonavida B: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61:5137-5144, 2001
35. Golay J, Lazzari M, Facchinetti V, et al: CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98:3383-3389, 2001